• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said it terminated its proposed convertible preferred stock offering due to current market conditions. The company, which is developing cancer drug PV-10, had filed a preliminary prospectus supplement in September. Shares of Provectus (NASDAQ:PVCT) gained 12 cents, or 23 percent, to close Thursday at 65 cents.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter